TIXiMED Chief Scientific Officer Interviewed on Taking the Pulse: A Health Care Podcast
Anath Shalev, M.D., the Chief Scientific Officer of TIXiMED, Inc., recently appeared as a guest on Taking the Pulse: A Health Care Podcast. On the podcast, Dr. Shalev, who serves as the Chief Clinical Officer and Director of the Comprehensive Diabetes Center at the University of Alabama at Birmingham (UAB), discusses recent advancements in type 1 diabetes research as well as cutting-edge treatments and novel drug therapies.
TIXiMED Chief Scientific Officer Authors Study Published in Diabetes
In a study published in Diabetes, Anath Shalev, M.D. and Guanlan Xu, Ph.D. examine the mechanism underlying verapamil’s beneficial effect on type 1 diabetes. According to Dr. Shalev, the study’s results “reveal IGF-1 signaling as yet another previously unappreciated pathway affected by verapamil and TXNIP that may contribute to the beneficial verapamil effects in the context of Type 1 diabetes.” Dr. Shalev is the Chief Scientific Officer of TIXiMED, Inc., a company developing and commercializing TXNIP inhibiting medications as therapeutics for type 1 and type 2 diabetes.
TIXiMED Chief Scientific Officer Presents at 2023 Immunology of Diabetes Society Congress
Renowned diabetes researcher and Chief Scientific Officer of TIXiMED Dr. Anath Shalev presented her work on verapamil and TXNIP inhibition at the 2023 Immunology of Diabetes Society Congress in Paris.